Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Sponsor: Brigham and Women's Hospital
Summary
To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.
Official title: A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2018-10-01
Completion Date
2024-06-01
Last Updated
2023-09-28
Healthy Volunteers
No
Conditions
Interventions
Alvimopan
To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
Placebo
To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States